Cardiovascular Systems Inc

Cardiovascular Systems — Q1 FY2022 Earnings Presentation

12 slides from Cardiovascular Systems's earnings presentation, Nov 9, 2021

  1. Slide 1: Q1 FY22 Earnings Supplement

    ©2021 Cardiovascular Systems, Inc. All Rights Reserved. Q1 FY22 Earnings Supplement November 9, 2021

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q1 FY22 Worldwide Revenues of $58.4 Million

    3.6% decrease vs. LY Q1 FY22 Worldwide Revenues of $58.4 Million Q1 FY22 Revenue Breakdown Worldwide Peripheral $39.0 -9.1% Y/Y -18.3% Q/Q Worldwide Coronary $19.4 +9.9% Y/Y -16.7% Q/Q Worldwide Peripheral Worldwide Coronary ($ in millions, Y/Y and Q/Q represent Year-over-Year and Quarter-over-Quart

  4. Slide 4: Q1 FY22: U.S. Peripheral

    Q1 FY22: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, ViperCath and WIRION COVID hospitali

  5. Slide 5: Q1 FY22: U.S. Coronary

    Q1 FY22: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary ViperWire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Modest Y/Y growth des

  6. Slide 6: Q1 FY22: International

    Q1 FY22: International Solid Y/Y growth driven by Japan and EU coronary 6 International revenue increased 94.3% Y/Y • International revenue increased 94.3% Y/Y driven by: • Strong growth in Japan with favorable Covid rebound Y/Y • EU launch plan remains on track and ahead of Japan CAD launch pace •

  7. Slide 7: Q1 FY22 vs. Q4 FY21 and Q1 FY21

    Q1 FY22 vs. Q4 FY21 and Q1 FY21 Dollars in thousands 7 Q1 FY22 Quarter/Quarter Change Year/Year Change Worldwide Revenue $58,370 -17.8% -3.6% Worldwide Peripheral Revenue $39,099 -18.3% -9.1% Worldwide Coronary Revenue $19,361 -16.7% 9.9% U.S. Revenue $55,042 -18.2% -6.4% U.S. Peripheral Revenue $38

  8. Slide 8: Q1 FY22: Select Financial Information

    Q1 FY22: Select Financial Information Dollars in thousands, except earnings per share 8 Q1 FY22 Q4 FY21 Q/Q Change Fav (Unfav) Q1 FY21 Y/Y Change Fav (Unfav) Net revenues $58,370 $70,987 ($12,617) $60,544 ($2,174) Cost of goods sold 14,308 20,634 6,326 12,564 (1,744) Gross Margin 75.5% 70.9%* Increa

  9. Slide 9: FY22: Annual Guidance

    FY22: Annual Guidance 9 For the fiscal year ending June 30, 2022, CSI anticipates: Revenue of $265 million to $285 million (2% to 10% growth); Gross profit as a percentage of revenues of approximately 75%; Net loss in a range of 5% to 8% of revenues; and Adjusted EBITDA of 1% to 4% of revenues.

  10. Slide 10: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 10 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  11. Slide 11: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2021 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are trademarks of Or

  12. Slide 12: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cS. www.csi360.com

Cardiovascular Systems — Q1 FY2022 Earnings Presentation on 6ix